about
A new multidisciplinary home care telemedicine system to monitor stable chronic human immunodeficiency virus-infected patients: a randomized studyHIV integrase inhibitors: a new era in the treatment of HIV.Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.Systemic inflammation and residual viraemia in HIV-positive adults on protease inhibitor monotherapy: a cross-sectional study.Nevirapine in the treatment of HIV.Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.Current perspectives on HIV-associated lipodystrophy syndrome.Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment.Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.An open-label, randomized study of the impact on insulin sensitivity, lipid profile and vascular inflammation by treatment with lopinavir/ritonavir or raltegravir in HIV-negative male volunteers.Low clinical relevance of risky alcohol consumption in a selected group of high adherent HIV-infected patients attended in the United Kingdom.Comparison of antiviral activity of regimens containing nucleos(t)ide (NUC) Pairs in HIV-Infected Patients Initiating REScue therapy (The NUCREST Study).Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.Genetic and functional mitochondrial assessment of HIV-infected patients developing HAART-related hyperlactatemia.Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients.Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine.Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors.Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.Mitochondrial effects of antiretroviral therapies in asymptomatic patients.Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals.Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study.[Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection].Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients.Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).Prospective observational study to evaluate the performance of the BioSure HIV Self-Test in the hands of lay users.Short communication: reversible mitochondrial respiratory chain impairment during symptomatic hyperlactatemia associated with antiretroviral therapy.Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy.Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1.Impact of lipodystrophy on the quality of life of HIV-1-infected patients.Intrathoracic fat in HIV-infected patients.Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutationsPharmacokinetic Study of Saquinavir 500 mg Plus Ritonavir (1000/100 mg Twice a Day) in HIV-Positive Pregnant Women
P50
Q28743362-2DBA127C-AEE9-4B4E-8FA4-0335BDE7BB0DQ30956943-3E684418-1EBD-44A9-9983-4EEC88C6FBD7Q33455840-A38331C3-30C7-4B88-B8EF-DD7E88404B34Q35218678-25DD5C2A-01F9-4312-A5FB-2A6724A27480Q35917412-B829B5EE-7879-4A08-9F42-A934F1E52304Q35944406-88711BB4-600A-49BF-90AC-E12F91B16AF8Q36132967-A8675960-0DE0-415E-9F8C-6BC6686703EFQ36765799-DB89E632-76CA-4FCF-B1DA-56401146EAC7Q38462726-9D642605-87C5-494E-A33B-C3B8CAB63FABQ40515614-CF78C50A-0916-4507-992B-6386F64237DEQ41663320-8C8E7AA6-F8F9-4B41-B0EC-2D10826509FCQ42787154-EE874771-2DF2-4796-A015-E3B71D1B8CD7Q43033610-077D0F5B-A105-4430-BED7-AC860B156EF7Q43271718-A53BFD09-0B1D-4F6C-B935-281124C7546CQ43408598-04832E35-6B0F-48BE-811C-EA87DC968CFFQ43636814-AD32F07D-5854-43F1-A42D-4A8370CA616FQ43653505-C46D8717-546F-476A-A911-AFCD1E3917F6Q43713490-76282A06-6270-4AB3-9473-E6DC5CA125E0Q44226223-E966DB21-FE8A-4A72-963F-A18E4F563679Q44669983-B277F9AA-C4B9-475C-AEEC-9B83680B7D05Q44807945-E8229A4B-CCAF-4913-B5D6-0E7C9B55DE06Q44811840-E3B24979-BA98-4845-9114-6EE44FCD4F2DQ44948765-2BA73F97-9BFA-4751-8CD7-81438593A716Q44964458-B61A9A83-7021-4185-B28F-1FE137480985Q45051217-13BB0ED4-61D1-47E4-830A-C0B129DA10DFQ45152103-9987090E-1DDE-45E4-9BB2-07F7CDC08DB4Q45257896-075700D0-AFA5-4ABA-B701-001C66B94560Q45387928-F869373D-1880-4753-8B01-8B496AEA5DFCQ46038574-352A97ED-E5FD-4231-A5CF-F1519CA047F7Q46469229-18423E05-7EA2-4B16-8366-08FCB622BD0EQ46511606-3DD9C68D-C69F-4C53-8CBA-1EE83FF3C67DQ47830535-C50D46AD-28DA-4B9A-99EA-B73D7D55AB81Q48327288-712DD52D-010A-4A2B-B94C-E90116921606Q51638512-62816E7E-9213-4576-A74A-F0441149B25EQ51650745-331EF659-0DA5-4175-98E2-07F1414B8A0AQ52553799-098320AC-9C62-4E64-905C-9B91BBFAC8AEQ53407240-83FFF6BB-5E1B-423D-8140-EB8B0EF69A8EQ53762515-DF48D00D-9621-4660-BB78-23E5B6CC562BQ56791533-85DF7916-F525-4E09-9325-A52E02519A6FQ58371359-4B1BF18B-80CF-4000-A750-DE52F8416302
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Ana Milinkovic
@ast
Ana Milinkovic
@en
Ana Milinkovic
@es
Ana Milinkovic
@nl
type
label
Ana Milinkovic
@ast
Ana Milinkovic
@en
Ana Milinkovic
@es
Ana Milinkovic
@nl
prefLabel
Ana Milinkovic
@ast
Ana Milinkovic
@en
Ana Milinkovic
@es
Ana Milinkovic
@nl
P214
P106
P21
P214
P31
P496
0000-0002-7732-9168